Advancing the Future of Long Non-Coding RNA (IncRNA) Medicine

Developing first-in-class therapies to precisely target disease-driving long non-coding RNAs (lncRNAs) in oncology and beyond
SCIENCE

LncRNAs: A Vast and Largely Untapped Therapeutic Landscape

Traditional drug development has focused on the ~2% of the genome encoding proteins, leaving ~98% — largely non-coding RNAs, including lncRNAs.
Predominantly uncharacterised, yet a handful of lncRNAs linked to major human diseases.
No approved drugs target lncRNAs — the opportunity to create next frontier first-in-class lncRNA medicine.
Traditional drug development has focused on the ~2% of the genome encoding proteins, leaving ~98% — largely non-coding RNAs, including lncRNAs
Largely uncharacterised, yet a handful of lncRNAs linked to major human diseases
No approved drugs target lncRNAs — the opportunity to create next frontier first-in-class lncRNA medicine
APPROACH

Turning lncRNA Biology into Precision Medicines

We employ systematic strategies and integrated proprietary platforms to discover, prioritise, and functionally characterise disease-relevant lncRNAs, and to target them with precision and effectiveness.

AMRQ-ARCANA

01
An advanced computational engine that discovers and prioritises disease-relevant lncRNAs.

AMRQ TARGET ID ATLAS

02
A curated atlas of functionally validated and high-confidence disease-relevant lncRNA targets.

AMRQ Drug Discovery (DD)

03
A dedicated drug discovery and development program focused on creating effective therapies that target pathogenic lncRNAs.

Amaroq is Focused on High Quality Program for Oncology First

Oncology programs are prioritised based on high unmet needs with best-in-class potential geared towards reliable delivery to specific organs, tissues and cells of interest.

PIPELINE

ONCOLOGY
Undisclosed Target 1
D
P
IND
Ph1
Ph2
Ph3
ONCOLOGY
Undisclosed Target 2
D
P
IND
Ph1
Ph2
Ph3

Core Team Members

Core Team Members

Dr Partha Das
CSO, Amaroq Tx
ex-Flagship Pioneering; ex-PI (currently Adjunct) Monash University; ex-Harvard: 20+ years of global experience across academia and industry, with deep expertise in RNA biology, epigenetics, gene regulation, and functional genomics.
Dr Hong Liu
Advisor & Contractor
ex-NextRNA, Takeda, Sanofi: Expert in computational genomics, systems biology, oncology and lncRNA discovery.
Dr Sarah Meidinger
Operations Manager, Amaroq Tx
ex-TamoRx and Upside Biotechnologies: Experienced biotech startup operations and project manager with a PhD from the University of Auckland.
Dr Sarah Herridge
Founder & Advisor
Director BioNTech; ex-PI Otago University, Founder & ex-CSO Amaroq: 20+ years experience in IncRNA and oncology research.

Board of Directors

Board of Directors

Dr Phil Kearney
Board of Director Chair
ex-Merck, Santaris, Axelia Oncology: 25+ years of biotech leadership across oncology, RNA therapeutics, and licensing.
Aizaz Syed
Board of Director & Senior Investment & Portfolio Manager, Tenmile
ex-Merrill Lynch: 10+ years of investment experience and venture capital, biotech and healthcare investing, investment banking; oversees investment, strategic growth, and partnerships for Amaroq.
David Christensen
Board of Director & CEO, Otago Innovation
20+ years of experience in commercialisation, banking and finance.

Scientific Advisory  Board (SAB)

Scientific Advisory Board (SAB)

Dr Henrik Oerum
CSO, Civi Biotech; ex-Santaris & Exiqon, Roche
ASO expert and drug developer.
Prof David Spector
Professor & Research Director, CSHL
World leader and 40+yrs research experience in lncRNAs and cancer biology.

Our partners
& investors

Our partners  & investors

Our partners  & investors

Contact Us
Contact Us